SRCIN1 and breast cancer: In a subgroup analysis of the patients of this TGCA cohort, stratified for the different BC molecular subtypes (i.e. luminal, HER2+ and triple-negative-TNBC), we found that, compared to luminal and HER2+ patients, TNBC patients showed significantly reduced expression levels of SRCIN1 transcript and p140Cap protein levels (Supplementary Fig. 3a), indicating that BC with clinico-pathological features of aggressiveness, such as TNBCs, display comparatively lower level of the tumor suppressor p140Cap.